natgillin/translations-raw huggingface dataset:
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use. 
Njegov namen je pojasniti, kako je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) ocenil predloženo dokumentacijo, na podlagi katere je oblikoval priporočila glede pogojev uporabe zdravila.
What are the precautions for the person who gives the medicine or comes 
Kakšne previdnostne ukrepe mora upoštevati oseba, ki daje zdravilo ali
They disappear once treatment has stopped. 
Po končanem zdravljenju izzvenijo.
The European Commission granted a marketing authorisation valid throughout the European Union, for Flexicam on 10 April 2006 and an extension to Flexicam 5mg/ml solution for injection on 9 December 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Flexicam, veljavno po vsej Evropski uniji, odobrila dne 10. aprila 2006, podaljšanje dovoljenja za promet z zdravilom Flexicam 5mg/ml raztopina za injiciranje pa 9. decembra 2008.
What benefit has Flexicam shown during the studies? 
Kakšne koristi je zdravilo Flexicam izkazalo med študijami?
If the product is swallowed by a person, the advice of a doctor should be sought immediately. 
Če oseba zaužije zdravilo nenamerno, se je treba nemudoma posvetovati z zdravnikom.
A study looked at how Flexicam was absorbed and its effects in the body, in comparison with Metacam 
V študiji so proučevali absorbiranje zdravila Flexicam ter njegove učinke na telo v primerjavi z zdravilom Metacam
Presentations of Flexicam oral suspension were subsequently not renewed. 
Dovoljenja za promet s farmacevtskimi oblikami zdravila Flexicam peroralna suspenzija posledično niso bila podaljšana.
What is the risk associated with Flexicam? 
Kakšna tveganja so povezana z zdravilom Flexicam?
The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Flexicam has been shown to be bioequivalent to Metacam 1.5 mg/ml oral suspension. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je menil, da se je zdravilo Flexicam v skladu z zahtevami Evropske unije izkazalo kot biološko enakovredno zdravilu Metacam 1,5 mg/ml peroralna suspenzija.
Flexicam was presented as a pale green oral suspension (1.5mg/ml) for dogs (to be given mixed with food) and a yellow solution for injection (5mg/ml) for dogs and cats. 
Zdravilo Flexicam je na voljo kot svetlo zelena peroralna suspenzija (1,5 mg/ml) za pse (ki se zmeša s hrano) in rumena raztopina za injiciranje (5 mg/ml) za pse in mačke.
Flexicam has been investigated in comparison with Metacam which is already authorised in the EU. 
Zdravilo Flexicam so primerjali z zdravilom Metacam, ki že ima dovoljenje za promet v EU.
Flexicam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs). 
Zdravilo Flexicam vsebuje meloksikam, ki spada v skupino zdravil, imenovanih nesteroidna protivnetna zdravila (NSAID).
Meloxicam acts by inhibition of prostaglandin synthesis. 
Meloksikam deluje tako, da zavira sintezo prostaglandinov.
Flexicam should not be administered to pregnant or lactating animals as the safety of the product has not been established in these cases. 
Zdravilo Flexicam se ne sme uporabljati pri brejih živalih ali živalih v obdobju laktacije, ker varnost zdravila v teh primerih ni bila ugotovljena.
Why has Flexicam been approved? 
Zakaj je bilo zdravilo Flexicam odobreno?
Flexicam should also not be used in animals suffering from gastrointestinal or hemorrhagic disorders and impaired renal or hepatic function, animals with known hypersensitivity to NSAIDs, and animals less than 6 weeks of age or in cats of less than 2 kg. 
Zdravilo Flexicam se ne sme uporabljati pri živalih z obolenji prebavil ali hemoragičnimi obolenji ter pri motnjah jetrne ali ledvične funkcije, živalih z ugotovljeno preobčutljivostjo na nesteroidna protivnetna zdravila ter živalih, mlajših od 6 tednov, ali mačkah, lažjih
Studies have been carried out to prove that Flexicam is ‘bioequivalent' to the reference veterinary medicine: this means that Flexicam is equivalent to Metacam 1.5 mg/ml suspension in the way it is absorbed and used by the body. 
Študije so pokazale, da je zdravilo Flexicam „biološko enakovredno“ referenčnemu veterinarskemu zdravilu - to pomeni, da se zdravilo Flexicam v telesu absorbira in uporablja enako kot zdravilo Metacam 1,5 mg/ml suspenzija.
What is Flexicam used for? 
Za kaj se zdravilo Flexicam uporablja?
An oral follow-up therapy using meloxicam or other NSAIDs should not be used in cats, as no safe dosage for repeated oral administration has been established. 
Pri mačkah zdravljenja ne smete nadaljevati s peroralno obliko meloksikama ali drugega nesteroidnega protivnetnega zdravila, ker pri njih še ni določen varen odmerek za nadaljevalno peroralno zdravljenje.
Flexicam contains meloxicam which belongs to a class of medicines having anti-inflammatory action. 
Zdravilo Flexicam vsebuje meloksikam, ki spada v skupino zdravil s protivnetnim delovanjem.
Occasional side effects of Flexicam are those seen with NSAIDs, such as loss of appetite, vomiting, diarrhoea, blood appearing in the stools and apathy (lack of vitality). 
Občasni neželeni učinki zdravila Flexicam so enaki kot pri drugih nesteroidnih protivnetnih zdravilih in obsegajo izgubo teka, bruhanje, drisko, kri v blatu in apatijo (pomanjkanje vitalnosti).
As the prostaglandins are substances that trigger inflammation, pain, exudation and fever, meloxicam 
Prostaglandini so snovi, ki sprožajo vnetje, bolečino, izločanje tekočine in zvišano telesno temperaturo, meloksikam pa zmanjša
The CVMP concluded that the benefits of Flexicam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of postoperative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Flexicam be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Flexicam pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišičnoskeletnih obolenjih, lajšanju pooperativne bolečine in vnetja po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah večje od z njim povezanih tveganj, in priporočil, da se za zdravilo Flexicam odobri dovoljenje za promet.
Flexicam is efficacious in alleviating the inflammation and pain in both acute and chronic musculoskeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in 
Zdravilo Flexicam je učinkovito pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih ter lajšanju pooperativne bolečine po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah
Flexicam is a ‘generic': this means that Flexicam is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam 1.5 mg/ml oral suspension). 
To pomeni, da je podobno „referenčnemu veterinarskemu zdravilu“, ki je že bilo odobreno v EU (zdravilu Metacam 1,5 mg/ml peroralna suspenzija).
How does Flexicam work? 
Kako je bilo zdravilo Flexicam raziskano?
This can reduce the symptoms of gout. 
To lahko zmanjša simptome protina.
The full EPAR for Febuxostat Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Febuksostat Mylan je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Febuxostat Mylan should be started 2 days before chemotherapy and continued for at least 7 days. 
Zdravljenje z zdravilom Febuksostat Mylan je treba začeti dva dni pred kemoterapijo in nadaljevati najmanj sedem dni.
The Committee recommended that Febuxostat Mylan be approved for use in the EU. 
Priporočil je, da se zdravilo Febuksostat Mylan odobri za uporabo v EU.
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Adenuric, and do not need to be repeated for Febuxostat Mylan. 
Študije o koristih in tveganjih zdravilne učinkovine pri odobrenih načinih uporabe so že bile izvedene z referenčnim zdravilom Adenuric, zato jih ni treba ponoviti za zdravilo Febuksostat Mylan.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Febuxostat Mylan has been shown to have comparable quality and to be bioequivalent to Adenuric. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Febuksostat Mylan primerljivo raven kakovosti kot zdravilo Adenuric ter da mu je biološko enakovredno.
This is a summary of the European public assessment report (EPAR) for Febuxostat Mylan. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Febuksostat Mylan.
This usually reduces blood uric acid levels within two weeks, but the dose can be increased to 120 mg once a day if blood uric acid levels remain high (above 6 mg per decilitre) after two to four weeks. 
To običajno zniža koncentracijo sečne kisline v krvi v dveh tednih, vendar pa je mogoče v primeru, če ostane koncentracija sečne kisline v krvi po dveh do štirih tednih visoka (nad 6 mg na deciliter), odmerek povečati na 120 mg enkrat na dan.
Because Febuxostat Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Febuksostat Mylan generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
What measures are being taken to ensure the safe and effective use of Febuxostat Mylan? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Febuksostat Mylan?
It works by blocking an enzyme called xanthine oxidase, which is needed to make uric acid in the body. 
Deluje tako, da zavira encim, imenovan ksantinska oksidaza, ki je potreben za tvorbo sečne kisline v telesu.
Attacks of gout can still occur during the first few months of treatment, so it is recommended that patients take other medicines to prevent attacks of gout for at least the first six months of treatment with Febuxostat Mylan. 
V prvih nekaj mesecih zdravljenja še vedno lahko pride do zagonov protina, zato je priporočljivo, da bolnik vsaj prvih šest mesecev zdravljenja z zdravilom Febuksostat Mylan jemlje druga zdravila za njihovo preprečevanje.
This means that Febuxostat Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Adenuric. 
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot referenčno zdravilo Adenuric, ki je že odobreno v Evropski uniji (EU).
As for every medicine, the company provided studies on the quality of Febuxostat Mylan. 
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Febuksostat Mylan.
When this happens in the joints and causes pain, it is known as ‘gout'. 
Kadar pride do odlaganja v sklepih, ki povzroča bolečino, to imenujemo „protin“ ali „putika“.
For more information about treatment with Febuxostat Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Febuksostat Mylan preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Febuxostat Mylan have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Febuksostat Mylan upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What are the benefits and risks of Febuxostat Mylan? 
Kakšne so koristi in tveganja, povezani z zdravilom Febuksostat Mylan?
In patients who are on chemotherapy a reduction in uric acid levels is expected to reduce the risk of tumour lysis syndrome. 
Pri bolnikih, ki prejemajo kemoterapijo, naj bi zmanjšanje ravni sečne kisline po pričakovanjih zmanjšalo tveganje za sindrom tumorske lize.
Febuxostat Mylan is available as tablets (80 and 120 mg) and can only be obtained with a prescription. 
Zdravilo Febuksostat Mylan je na voljo v obliki tablet (80 in 120 mg), njegovo predpisovanje in izdaja je le na recept.
For the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy, the recommended dose is 120 mg once a day. 
Za preprečevanje in zdravljenje hiperurikemije pri bolnikih, ki prejemajo kemoterapijo, je priporočeni odmerek 120 mg enkrat dnevno.
For practical information about using Febuxostat Mylan, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Febuksostat Mylan naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Keeping uric acid levels low for long enough can also shrink tophi. 
Vzdrževanje koncentracije sečne kisline na nizki ravni dovolj dolgo lahko zmanjša tudi velikost tofov.
For the treatment of long-term hyperuricaemia, the recommended dose of Febuxostat Mylan is 80 mg once a day. 
Pri zdravljenju dolgotrajne hiperurikemije je priporočeni odmerek zdravila Febuksostat Mylan 80 mg enkrat na dan.
Febuxostat Mylan is used in patients who have signs of a build-up of crystals, including gouty arthritis (pain and inflammation in the joints) or tophi (‘stones', larger deposits of urate crystals that can cause joint and bone damage). 
Zdravilo Febuksostat Mylan se uporablja pri bolnikih, ki kažejo znake odlaganja kristalov, vključno s protinskim artritisom (bolečino in vnetjem v sklepih) ali tofi („kamni“večjimi skupki kristalov urata, ki lahko povzročijo poškodbe sklepov in kosti).
Hyperuricaemia can lead to urate crystals forming and building up in the joints and the kidneys. 
Hiperurikemija lahko privede do tvorbe kristalov urata in njihovega odlaganja v sklepih in ledvicah.
Febuxostat Mylan is also used to treat and prevent high levels of uric acid in the blood in adults with blood cancers who are receiving chemotherapy (medicines to treat cancer) and at risk of tumour lysis syndrome (a complication due to the breakdown of cancer cells causing a sudden rise of uric acid in the blood which can cause damage to the kidneys). 
Zdravilo Febuksostat Mylan se uporablja tudi za zdravljenje in preprečevanje visokih ravni sečne kisline v krvi pri odraslih s krvnim rakom, ki prejemajo kemoterapijo (zdravila za zdravljenje raka) in so izpostavljeni tveganju za sindrom tumorske lize (zapletu zaradi razgradnje rakavih celic, ki povzroči nenadno povečanje sečne kisline v krvi, kar lahko privede do okvare ledvic).
What is Febuxostat Mylan and what is it used for? 
Kaj je zdravilo Febuksostat Mylan in za kaj se uporablja?
Febuxostat Mylan contains the active substance febuxostat and is a ‘generic medicine'. 
Zdravilo Febuksostat Mylan vsebuje zdravilno učinkovino febuksostat in je „generično zdravilo“.
By reducing the production of uric acid, Febuxostat Mylan can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up. 
Z zmanjševanjem tvorbe sečne kisline lahko zdravilo Febuksostat Mylan zniža njeno koncentracijo v krvi in jo vzdržuje na nizki ravni ter tako ustavi kopičenje kristalov.
Therefore, the CHMP's view was that, as for Adenuric, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi enako kot pri zdravilu Adenuric odtehtajo znana tveganja.
Febuxostat Mylan is a medicine used to treat adults with long-term hyperuricaemia (high levels of uric acid or ‘urate' in the blood). 
Zdravilo Febuksostat Mylan se uporablja za zdravljenje odraslih z dolgotrajno hiperurikemijo (visokimi koncentracijami sečne kisline ali urata v krvi).
Febuxostat Mylan febuxostat 
Febuksostat Mylan febuksostat
It is not intended to provide practical advice on how to use Febuxostat Mylan. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Other information about Febuxostat Mylan 
Druge informacije o zdravilu Febuksostat Mylan
Why is Febuxostat Mylan approved? 
Zakaj je bilo zdravilo Febuksostat Mylan odobreno?
The active substance in Febuxostat Mylan, febuxostat, reduces the formation of uric acid. 
Zdravilna učinkovina zdravila Febuksostat Mylan, febuksostat, zmanjša tvorjenje sečne kisline.
How is Febuxostat Mylan used? 
Kako se zdravilo Febuksostat Mylan uporablja?
Febuxostat Mylan treatment should not be stopped if an attack of gout occurs. 
V primeru zagona protina se zdravljenje z zdravilom Febuksostat Mylan ne sme prekiniti.
How does Febuxostat Mylan work? 
Kako zdravilo Febuksostat Mylan deluje?
How has Febuxostat Mylan been studied? 
Kako je bilo zdravilo Febuksostat Mylan raziskano?
The procedure should be carried out under sterile conditions. 
Postopek je treba izvajati v sterilnih pogojih.
What measures are being taken to ensure the safe and effective use of Jetrea? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Jetrea?
The European Commission granted a marketing authorisation valid throughout the European Union for Jetrea on 13 March 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Jetrea, veljavno po vsej Evropski uniji, izdala 13. marca 2013.
The other eye should not be treated with Jetrea for at least 7 days. 
Drugo oko se z zdravilom Jetrea ne sme zdraviti najmanj sedem dni.
The full EPAR for Jetrea can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Jetrea je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Jetrea. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Jetrea.
After 28 days, the results were that adhesions had cleared in 25% and 28% of patients who were given Jetrea injection (61 out of 219 and 62 out of 245), compared with 13% and 6% of those who received placebo (14 out of 107 and 5 out of 81). 
Po 28 dneh so rezultati pokazali odpravo adhezije pri 25 % oziroma 28 % (61 od 219 oziroma 62 od 245) bolnikov, ki so prejeli injekcijo zdravila Jetrea, v primerjavi s 13 % oziroma 6 % (14 od 107 oziroma 5 od 81) bolnikov, ki so prejeli placebo.
What benefits of Jetrea have been shown in studies? 
Kakšne koristi je zdravilo Jetrea izkazalo v študijah?
What is Jetrea and what is it used for? 
Kaj je zdravilo Jetrea in za kaj se uporablja?
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Jetrea outweigh its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Jetrea večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The recommended dose is 0.125 mg given as a single injection into the affected eye which should not be repeated. 
Priporočeni odmerek je 0,125 mg, ki se daje z enkratnim injiciranjem v prizadeto oko in se ne sme ponoviti.
Other information about Jetrea 
Druge informacije o zdravilu Jetrea
Although the effects shown were modest (resolution of vitreomacular adhesion in a quarter of patients), they were considered to be significant as treatment may improve vision and prevent the need for surgery. 
Čeprav so bili učinki zdravila skromni (odprava vitreaomakularne adhezije pri četrtini bolnikov), so bili ocenjeni kot pomembni, saj lahko zdravljenje izboljša vid in odpravi potrebo po kirurškem posegu.
Regarding its safety, the most common side effects were short-lived and considered manageable, and often occurred as a response to the injection procedure or were linked to the resolution of the disease itself. 
Kar zadeva varnost zdravila, so bili najpogostejši neželeni učinki kratkotrajni in ocenjeni kot obvladljivi ter so se pogosto pojavili kot odziv na injiciranje ali pa so bili povezani z odpravo same bolezni.
In two main studies involving 652 adults with vitreomacular adhesion and decreased vision, patients were given a single intravitreal injection of 0.125 mg Jetrea or a placebo injection (a dummy treatment). 
V dveh glavnih študijah, ki sta vključevali 652 odraslih z vitreomakularno adhezijo in poslabšanim vidom, so bolniki prejeli eno intravitrealno injekcijo 0,125 mg zdravila Jetrea ali injekcijo placeba (zdravila brez zdravilne učinkovine).
What are the risks associated with Jetrea? 
Kakšna tveganja so povezana z zdravilom Jetrea?
Why is Jetrea approved? 
Zakaj je bilo zdravilo Jetrea odobreno?
Jetrea must not be used in patients who have or are thought to have infections in or around the eyes. 
Zdravila Jetrea ne smejo uporabljati bolniki, ki imajo ali utegnejo imeti okužbo v očesu ali okoli njega.
It is not intended to provide practical advice on how to use Jetrea. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
It contains the active substance ocriplasmin. 
Vsebuje zdravilno učinkovino okriplazmin.
The most common side effects are vitreous floaters (small, often irregular, dark shapes in the field of vision), eye pain, photopsia (flashes of light in the field of vision) and chromatopsia (changes in colour perception), as well as conjunctival haemorrhage (bleeding of the membrane that lies over the white part of the eye). 
Najpogostejši neželeni učinki so delci v steklovini (majhne, temne pike, pogosto nepravilnih oblik, v vidnem polju), bolečina v očesu, fotopsija (utrinki svetlobe v vidnem polju) in kromatopsija (spremembe v zaznavanju barv) ter krvavitev v očesni veznici (krvavitev v membrani, ki prekriva beli del očesa).
Jetrea is a solution for injection into the eye. 
Zdravilo Jetrea je raztopina za injiciranje v oko.
For more information about treatment with Jetrea, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Jetrea preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Jetrea have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Jetrea upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The risk of more serious side effects such as decreased vision that is non-reversible, other changes to the retinal function or supporting structures of the lens appear to be small. 
Tveganje za resnejše neželene učinke, kot so trajno poslabšanje vida, druge spremembe delovanja mrežnice ali podpornih struktur leče, je majhno.
For practical information about using Jetrea, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Jetrea naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.